Skip to content

13F-HR filed by NOVO HOLDINGS A/S

NOVO HOLDINGS A/S filed this 13F-HR for the quarter ended 2026-09-30, accepted by EDGAR 2026-11-16 21:32:46 UTC, with 27 holding rows worth $1,489,688,141.

Accession
0001388325-26-000051
Filed
2026-11-16
Accepted by EDGAR
Ingested
Source
EDGAR live feed

Original filing

13F report for Q3 2026

A holdings report, 27 entries on the cover page, a total value of $1,489,688,141 stated on the cover page (in dollars after the unit check, H1), rows summing to $1,489,688,141 with VALUE read as dollars as filed, 13F file number 028-16231. The quarter's positions are built on this report. The resolved quarter.

The information table after summing rows of one CUSIP and put or call (H4), with the CUSIP and issuer name as filed. Values in dollars after the unit check (method).

Issuer as filedCUSIPClassAmountValueValue read asType
EDGEWISE THERAPEUTICS INC28036F105COM5,350,000$217,210,000dollars as filed
ASMLHLDGNVFSPONSOREDADR1ADRREPS1ORDSHSN07059210STOK94,946$172,010,820dollars as filed
BROOKFIELD CORP CL A LTD VT SH11271J107Stock4,465,035$162,795,176dollars as filed
HEMAB THERAPEUTICS HLDGS INC423494103COM SHS4,180,550$128,928,162dollars as filed
AVALYN PHARMA INC05348Y105COMMON STOCK3,449,191$98,267,452dollars as filed
MIRUM PHARMACEUTICALS INC604749101COM1,125,000$96,165,000dollars as filed
Salesforce.com, Inc79466L302COM393,187$90,263,940dollars as filed
ENLIVEN THERAPEUTICS INC COM29337E102Stock1,000,000$45,840,000dollars as filed
4D MOLECULAR THERAPEUTICS INC COM35104E100Stock3,000,000$42,930,000dollars as filed
Obsidian Therapeutics, Inc.67448A106Common Stock, $0.0001 par value per share3,123,992$42,892,410dollars as filed
VAXCYTE INC COM92243G108Stock710,000$40,399,000dollars as filed
FLOOR & DECOR HLDGS INC CL A339750101Stock797,000$36,510,570dollars as filed
VIRIDIAN THERAPEUTICS INC92790C104COM1,750,000$36,032,500dollars as filed
ARRIVENT BIOPHARMA INC04272N102COM1,175,000$35,579,000dollars as filed
INSMED INC COM PAR $.01457669307Stock284,425$32,464,270dollars as filed
PHARVARIS NVN69605108COMMON STOCK1,019,426$32,336,193dollars as filed
CELLDEX THERAPEUTICS INC NEW15117B202COM NEW950,000$30,789,500dollars as filed
ALIBABA GROUP HLDG LTD01609W102SPONSORED ADS257,327$27,672,946dollars as filed
XENON PHARMACEUTICALS INC COM98420N105Stock652,105$24,251,785dollars as filed
SCHOLAR ROCK HLDG CORP80706P103COM460,002$22,227,297dollars as filed
DYNE THERAPEUTICS INC COM26818M108Stock1,376,164$22,170,002dollars as filed
MAPLIGHT THERAPEUTICS INC56565P103COMMON STOCK2,086,622$21,262,678dollars as filed
CONTINEUM THERAPEUTICS INC CL A21217B100Stock704,013$9,447,854dollars as filed
ALUMIS INC022307102COM1,250,000$9,237,500dollars as filed
BRIDGEBIO ONCOLOGY THERAPEUT107924102COM NEW2,250,000$9,225,000dollars as filed
MARQETA INC57142B104CLASS A COM110,389$1,876,061dollars as filed
LANZATECH GLOBAL INC51655R200CMN158,148$903,025dollars as filed

Amendment chain

FilingRoleFiledAcceptedIngested
13F-HR 0001388325-26-000051this filing2026-11-16